特集 神経疾患治療の進歩2021
免疫介在性中枢神経疾患
2022 年 39 巻 5 号 p. 764-767
詳細
2022 年 39 巻 5 号 p. 764-767
Recent advances and new findings relating to multiple sclerosis (MS) and other inflammatory disorders in the central nervous system were reviewed. The following topics were discussed : the association between disease modifying therapy (DMT) of MS and coronavirus infectious disease–19 (COVID–19), the association between DMT initiation strategy and MS disability progression, the real world data on MS DMT and pregnancy, the association between expansion of chronic lesions and disease progression in relapsing–remitting MS, the efficacy of prednisolone monotherapy for neuromyelitis optica spectrum disorder (NMOSD), the clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and the brain structural alterations in MOGAD measured by multimodal MRI.
